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 Early detection of COVID-19 is essential, even more in
patients with nonesmall-cell lung cancer, who are
already at higher risk of developing severe
pneumonitis.
 Differential diagnosis from toxicities induced by
radiotherapy or immunotherapy is challenging, as
clinical and radiologic presentation might almost
completely overlap.
 As stage III nonesmall-cell lung cancer is curable in
about 40% of cases, an aggressive and timely treat-
ment appears mandatory.
Immune-checkpoint inhibitors could possibly
augment the detrimental cytokine release, crucial
in Covid-19 pathogenesis.Clinical Lung Cancer, Vol. -, No. -, --- ª 2020 Elsevier Inc. All rights reserved.
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The Coronavirus-disease-2019 (Covid-19) outbreak is currently
generating an overwhelming burden for public health worldwide: as
of May 16, 2020, 4,425,485 confirmed cases had been listed and
302,059 deaths reported.1 The clinical presentation of Covid-19 is
heterogeneous, lacks pathognomonic signs, and mostly overlaps
with other affections of the respiratory system.2 Management of this
condition is even more challenging in patients with nonesmall-cell
lung cancer (NSCLC) because they are more vulnerable to develop
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https://doi.org/10.1016/j.cllc.2020.05.027anticancer therapy could resemble Covid-19. Maintenance therapy
with the programmed death-ligand 1 (PD-L1) inhibitor durvalumab
is currently the standard of care for stage III unresectable NSCLC
after concurrent radio-chemotherapy (RCT), with a reported inci-
dence of pneumonitis of 33.9% (grade  3 in 3.4%).3 Herein, we
present the first report to date of a case of Covid-19 during dur-
valumab, focused on the differential diagnosis between radiation-
induced pneumonitis and PD-L1 immune checkpoint inhibitor
toxicity in a patient with NSCLC.
Case Report
A 75-year-old man underwent an abdominal computed tomog-
raphy (CT) scan for diverticulitis, with the incidental finding of a
lesion of the lower right lung lobe (17  17 mm) with ipsilateral
hilar-mediastinal lymphadenopathies. A bronchoscopic biopsy was
performed, with histologic diagnosis of adenocarcinoma with
PD-L1 expression > 90% and wild-type EGFR, ALK, and ROS1.
A positron emission tomography-CT scan showed pathologic up-
take of the known neoplastic sites; the tumor was staged cT1c cN2
M0, IIIA. Comorbidities included recurring diverticulitis, GOLDClinical Lung Cancer Month 2020 - 1
Figure 2 Chest Ct-Scan Showing a Pattern of Atypical
Immune-Related Pneumonitis After 4 Cycles of
Durvalumab
Figure 3 Chest Radiograph at Covid-19 Presentation,
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Covid-19 During Advanced NSCLC Treatmentstage I chronic obstructive pulmonary disease, hypertension, and
gastritis. Performance status was Eastern Cooperative Oncology
Group grade 1, as the only symptom was dyspnea on exertion, and
the patient was a smoker (about 100 pack/year). Our institutional
tumor board advised for concurrent chemo-radiotherapy (cCRT),
that was delivered with volumetric modulated arc therapy at a dose
of 60 Gy in 30 fractions to the primary tumor and mediastinal
nodes (levels 7 and 10R). Four cycles of concurrent chemotherapy
with paclitaxel and carboplatin were administered. A total body CT
scan was performed 15 days after cCRT, showing a partial response
of both the primary tumor and the subcarinal adenopathy, with the
disappearance of the hilar lymphadenopathy (Figure 1); no ground-
glass opacities or consolidations were detected. Maintenance with
durvalumab was started 27 days after cCRT end, and 4 cycles were
administered without associated toxicities or alteration of blood tests
(including liver, thyroid, and hypophysis function). On January 8,
2020, he presented for the fifth cycle, reporting fatigue, worsening
of the dyspnea, and non-productive cough; no pathologic findings
were detected at physical examination. Immunotherapy was dis-
continued, and a chest CT scan was requested. A pattern of atypical
immune-related pneumonitis was detected, with multifocal con-
solidations in the right lung involving the upper, middle, and lower
lobes, and surrounding the known lesion (Figure 2) and bilateral
diffuse interstitial thickening. It should be noted that, at that time,
Covid-19 was not considered among the differential diagnoses, as
the first direct transmission in Italy was reported on February 18,
2020. Oral prednisone 50 mg daily was started: after a week of
treatment, dyspnea markedly improved and returned to the baseline
condition. The steroid was gradually tapered, halving the dose every
week, and suspended after 4 weeks. Chest CT scan was repeated on
February 17, and findings were stable compared with the previous
evaluation. On March 4, he was admitted to restart durvalumab,
reporting the onset 2 days earlier of fever, unremitting dry cough,
and diarrhea, with dyspnea at rest. The physical examination
revealed bilateral diffuse crackles; peripheral oxygen saturation in
ambient air was 88%, heart rate was 120 bpm; arterial blood-gas testFigure 1 Total-Body Ct Scan was Performed 15 Days After
Radio-Chemotherapy, Showing Partial Response Of
Disease
nical Lung Cancer Month 2020showed normocapnic hypoxemia (PaO2 62 mmHg). Chest radi-
ography showed a diffuse alveolar and interstitial infiltrate, affecting
the right lung and the inferior field of the left lung (Figure 3).
Complete blood count, creatinine, and liver function were normal.
Nasopharyngeal swab resulted negative for influenza A-B, adeno-
virus, and respiratory syncytial virus; reverse-transcription poly-
merase-chain-reaction (RT-PCR) test resulted positive for
SARS-CoV-2, confirming the suspect of Covid-19. The patient
was then hospitalized and started treatment with lopinavir/ritonavir,
oseltamivir, and hydroxychloroquine and prophylactic antibiotic
therapy with azithromycin and piperacillin/tazobactam. Clinical
conditions abruptly deteriorated, and dyspnea did not improve
despite oxygen therapy at increasing volumes. Owing to the over-
whelmingly high number of patients treated at our hospital inten-
sive care unit during the Covid-19 outbreak, mechanical ventilationPresenting Bilateral Diffuse Alveolar and Interstitial
Infiltrate
Andrea Emanuele Guerini et alcould not be promptly performed. His respiratory function wors-
ened, and the patient died of respiratory failure on March 7, 2020.
Discussion
Pneumonitis is quite common in advanced NSCLC and can be a
consequence of the disease itself, super-infections, coexisting lung
dysfunctions, or side effects of the treatment. Recently, Covid-19
has been added to the list of possible causes, emerging as a real
threat for already frail patients.
Covid-19 Pneumonitis
Clinical presentation of Covid-19 is aspecific. Many patients are
asymptomatic or express mild symptoms, resulting in under-
detection of the total cases.4 Fever is present in most patients, and
common symptoms encompass cough, malaise, and myalgia.3-5
Laboratory findings include lymphopenia, thrombocytopenia, and
increased C-reactive protein.5 Up to 20% of the cases might develop
severe disease, characterized by dyspnea, tachypnea, and hypoxemia
requiring hospitalization; about 5% to 10% of the patients pre-
cipitate, often suddenly, into critical conditions, including respira-
tory failure and multi-organ dysfunction.3-5 Lung involvement is
typically bilateral, peripheral, and basal in the vast majority of the
cases. It usually presents with multifocal ground-glass opacities
(GGO) and interstitial infiltrations, which may evolve into con-
solidations and ‘crazy paving’ patterns; complete clearing usually
needs several weeks.5,6 Current treatment includes antiviral agents,
and the antimalarial immune-modulator chloroquine.3-7 In severe
cases, oxygen therapy and prophylactic antibiotics are administered,
whereas the use of glucocorticoids is debated.3-8 About 5% to 10%
of the patients necessitate admission in intensive care units, most of
them requiring mechanical ventilation.3
Radiation-induced Pneumonitis
The incidence of pneumonitis in patients undergoing radical RT for
NSCLC varies from 5% to 25%.9-11 Chest CT is the elective tech-
nique both for diagnosis and follow-up.10,11 Damage is usually limited
to the irradiated volume and surrounding tissue. Nevertheless, a mi-
nority of the cases develop ‘out-of-field’ or bilateral involvement owing
to immune-mediated reactions.10,11 Initially, a patchy ground-glass
attenuation can be observed, with a possible gradual evolution over
weeks or months towards consolidation and finally to fibrosis.10,11
Radiologic and clinical changes may appear many months after RT
and resemble disease progression.10 The mainstay of the treatment of
symptomatic cases is oral glucocorticoids. Most of the patients
ameliorate after a few weeks of treatment, followed by a very slow
tapering to avoid relapses.10,11 Less than 5% of cases are grade 3 and
necessitate hospitalization.9 Recover of pulmonary function requires
several months, and a few patients develop irreversible and occasionally
fatal respiratory failure.11
Immune Checkpoint Inhibitor-induced Pneumonitis
The incidence of pneumonitis caused by programmed cell death
protein-1 (PD-1)/PD-L1 inhibitors is 3% to 5% in clinical trials, and
up to 19% in ‘real-world’ cohorts, with increased risk for previous
radiotherapy.12-14 Immune-related events appear within an ample
range of time to onset and even months after treatmentdiscontinuation.12,14,15 Chest CT scan usually shows a bilateral
multifocal interstitial pattern with non-segmental GGO or consoli-
dations involving especially the lower lungs, septal thickening, and
traction bronchiectasis.12-14 Atypical patterns are frequent and
encompass interstitial pneumonitis, GGO around the tumor (peri-
tumoral infiltration), opacities in the ipsilateral lung, and aggravation,
or ‘recall,’ of radiation-induced fibrosis.14,16 In grade 1 to 2 pneu-
monitis, immunotherapy must be temporarily withheld, and oral
steroids should be administered with close clinical and radiologic
monitoring and gradually tapered after response. In the absence of
improvement or grade  3 toxicity, the drug should be permanently
suspended, and high-dose steroids started in a hospital setting.12,13
The steroid-refractory disease is uncommon; it may require the
addition of further immunosuppressors but is characterized by high
mortality.12
Pathogenesis
The data summarized above highlight the remarkable similarity
between different patterns of pneumonitis caused by either radiation
or immunotherapy and Covid-19. A plausible assumption could be
that Covid-19 pneumonia is at least partly owing to a dispropor-
tionate release of inflammatory molecules. This phenomenon could
explain the higher levels of cytokines including interleukin-6 and
tumor necrosis factor measured in patients developing severe res-
piratory symptoms17 and the investigation of immunosuppressants
such as chloroquine and tocilizumab (a humanized monoclonal
antibody targeting interleukin-6 receptor, also used to manage
steroid-refractory pneumonitis induced by PD-L1 inhibitors) for
Covid-19 treatment.18,19 The activity of the PD-1/PD-L1 axis does
not only induce immunotolerance towards neoplastic cells but also
avoids excessive and unregulated activation of the immune system
during the acute phase of viral infections.20 Therefore, immune-
checkpoint inhibitors could also augment the detrimental cyto-
kine release induced by Covid-19.
Conclusions
This report outlines the complexity and the importance of early
detection of Covid-19, even more in patients with NSCLC, who
are already at higher risk of developing severe pneumonitis on a
multi-factorial basis. Nevertheless, differential diagnosis from tox-
icities induced by radiotherapy or immunotherapy is challenging,
as clinical and radiologic presentation might almost completely
overlap. In order to face the Covid-19 emergency, we implemented
a dedicated workflow to allow a timely diagnosis. In case of
contacts at risk or at the onset of respiratory symptoms or fever,
RT-PCR for Sars-Cov-2 on nasopharyngeal swab should be
immediately performed. Although chest radiograph assessed with a
validated score21 could be useful as a first-line test, CT scan is
recommended in all the suspect cases owing to its elevated sensi-
tivity and should be repeated to monitor the evolution of disease.
Considering that stage III NSCLC is curable in about 40% of
cases, an aggressive and prompt treatment appears mandatory, also
taking into account the presumptive susceptibility to develop severe
Covid-19 presentations.
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